Glomus Tumor

1. Clinical Overview

Summary

A Glomus Tumor is a rare, benign, but exquisitely painful vascular neoplasm arising from the glomus body (Sucquet-Hoyer canal). The glomus body is a specialized arteriovenous anastomosis involved in thermoregulation, located in the reticular dermis, most abundantly in the fingertips (specifically the nail bed). [1,2] These tumors account for 1-5% of hand tumors but cause disproportionate morbidity due to severe, paroxysmal pain. [3,4]

The classic clinical picture is the "Glomus Triad":

1. Severe Paroxysmal Pain.
2. Pinpoint Tenderness.
3. Cold Intolerance (Pain triggered by cold water/weather). [5,6]

Diagnosis is primarily clinical, supported by three key tests: Love's Pin Test, Hildreth's Test, and the Cold Sensitivity Test. MRI is the gold standard imaging modality (T2-bright nidus) with sensitivity of 82-90% and specificity of 50-60%, but false negatives occur with small (less than 3mm) lesions. [7,8] Ultrasound, particularly high-frequency (15-22 MHz), has emerged as a valuable diagnostic tool with sensitivity up to 86%. [9,10]

Management is strictly surgical excision. Complete removal of the capsule is curative with immediate pain relief in 90-95% of cases. Incomplete excision leads to recurrence rates of 10-33% depending on surgical approach and tumor location. [11,12,13]

Key Facts

• Size: Usually tiny (less than 1 cm, often 3-5mm). The pain is disproportionate to size. [14]
• Location: 75% occur in the hand, 65% of those are subungual (under the nail). Extra-digital tumors occur in 10-15% of cases. [15,16]
• Gender: F:M ratio is 2-3:1 for subungual tumors. Extra-digital tumors show male predominance. [17,18]
• Age: Peak incidence 30-50 years (range 10-80 years). [19]
• Pathology: WHO classifies three variants: glomus tumor proper (75%), glomangioma (20%), and glomangiomyoma (5%). [20]

Clinical Pearls

Clinical Pearl: The "Blue Dot": Look closely at the nail plate. A subtle blue/red discoloration (erythronychia) under the lunula is highly suggestive, present in 20-30% of cases. It may look like a splinter hemorrhage that never grows out. [21]

Clinical Pearl: The "Ice Cube" Sign: Patients may wear gloves even in summer or refuse to wash dishes in cold water. Ask specifically: "Does putting your hand in the freezer hurt?" -> If yes, think Glomus. Cold sensitivity is reported in 60-100% of cases. [22,23]

Clinical Pearl: The "Phantom" Tumor: Many patients see multiple doctors (GP, Neuro, Ortho) over years before diagnosis (average delay 4-7 years) because the tumor is invisible and the pain seems "neuropathic". They are often mislabeled as CRPS or "psychogenic". [24,25]

Clinical Pearl: Hildreth's Magic: Inflating a tourniquet makes the pain disappear. Releasing it causes a massive throb. This vascular dependence (sensitivity 92%, specificity 91%) helps differentiate it from a Neuroma (which hurts regardless of blood flow). [26,27]

Clinical Pearl: Onychoscopy: Dermoscopy of the nail can reveal purple-red discoloration, nail plate thinning, and longitudinal erythronychia in 55-75% of cases, aiding non-invasive diagnosis. [28]

Why This Matters Clinically

Curable Misery: Patients suffer for years with debilitating pain. A simple 20-minute surgery provides an instant "cure" with satisfaction rates exceeding 90%. [29] Nail Dystrophy: Chronic pressure on the germinal matrix causes permanent nail splitting/ridging in 10-20% of untreated cases if left more than 5 years. [30]

---

2. Epidemiology

Incidence

• Rare: Glomus tumors represent 1.6-4.5% of all hand soft tissue tumors in large surgical series. [31,32]
• Age: Peak incidence 30-50 years (mean 40-45 years). Rare in children (less than 5% of cases). [33]
• Sex:
  • Subungual tumors: Female predominance (F:M = 2-3:1). [34]
  • Extra-digital tumors: Male predominance (M:F = 2:1). [35]
• Genetics: Most are sporadic. Multiple Glomus Tumors (Glomangiomatosis) occur in 10-15% of cases and can be familial (Autosomal Dominant, Chromosome 1p21-22 mutation) but represent less than 5% of all glomus tumors. [36,37]

Anatomical Distribution

• Subungual (Finger): 65-75% (Most common - thumb and index finger). [38]
• Pulp (Finger pad): 15-20%. [39]
• Rest of Body: 10-15% (Knee, Elbow, Wrist, Forearm, Trunk - often misdiagnosed). [40]
• Visceral: Extremely rare (gastric, pulmonary) - less than 1%. [41]

Risk Factors

• Occupation: Manual workers and cold exposure occupations (no proven association but anecdotal). [42]
• Trauma: No consistent association, though some patients report antecedent trauma. [43]

---

3. Pathophysiology

The Glomus Body (Normal Anatomy)

The Glomus apparatus is a specialized neuromyoarterial shunt between an arteriole and a venule, bypassing the capillary bed. [44]

• Function: Thermoregulation. When cold, the shunt opens to divert blood away from the skin surface (conserving heat). When hot, it constricts to force blood to the surface (radiating heat). [45]
• Structure: The Sucquet-Hoyer canal is lined by endothelium and surrounded by concentric layers of glomus cells (modified smooth muscle cells). [46]
• Innervation: Richly supplied by sympathetic (vasomotor) and sensory nerve fibers (unmyelinated C fibers and myelinated Aδ fibers). This dense innervation explains the excruciating pain. [47,48]
• Distribution: Highest concentration in acral sites (fingertips, nail beds, palms, soles, ears). Estimated 200-600 glomus bodies per fingertip. [49]

3b. Anatomy of the Nail Unit (Surgical Landmarks)

3c. Histopathology (WHO Classification)

The WHO classifies glomus tumors into three distinct histological variants based on cellular composition: [50,51]

1. Glomus Tumor Proper (75% of cases)

• Cells: Uniform, round to polygonal glomus cells with round nuclei and eosinophilic cytoplasm.
• Architecture: Solid nests or sheets of glomus cells surrounding dilated vascular channels.
• Smooth Muscle: Minimal or absent.
• Vascular Component: Prominent capillary network.

2. Glomangioma (20% of cases)

• Cells: Fewer glomus cells.
• Architecture: Predominantly dilated, thick-walled vascular spaces resembling cavernous hemangioma.
• Clinical: Often multiple, less painful, may be congenital.

3. Glomangiomyoma (5% of cases)

• Cells: Transitional forms between glomus cells and smooth muscle cells.
• Architecture: Prominent smooth muscle component.
• Clinical: Deeper location, larger size, less specific pain.

Immunohistochemistry:

• Smooth Muscle Actin (SMA): Positive (confirms smooth muscle differentiation). [52]
• h-Caldesmon: Positive in glomus cells. [53]
• Type IV Collagen: Highlights basal lamina around cells. [54]
• Vimentin: Positive.
• S100: Negative (differentiates from neural tumors).

Malignant Glomus Tumor (Glomangiosarcoma): Extremely rare (less than 1% of glomus tumors). Criteria include: [55,56]

• Size greater than 2 cm, OR
• Deep location (subfascial), OR
• Atypical mitotic figures, OR
• Moderate to high nuclear grade AND mitotic activity greater than 5 per 50 HPF.

3d. Genetics and Molecular Pathology

Sporadic Tumors:

• Most are clonal neoplasms (not true hamartomas). [57]
• NOTCH pathway mutations: Recently identified in sporadic cases. [58]

Familial Glomangiomatosis:

• Chromosome 1p21-22: Mutations in the GLMN gene (glomulin) identified in autosomal dominant familial cases. [59,60]
• Glomulin acts as a tumor suppressor; loss leads to multiple glomus tumors.
• Penetrance: Variable (30-90%).

Stepwise Pathogenesis: Why it Hurts

Step 1: Neoplastic Proliferation

• Clonal proliferation of glomus cells leads to an encapsulated nodule.
• It is essentially a "Hypertrophic Glomus Body" with aberrant regulation. [61]

Step 2: Capsular Tension

• The tumor is encapsulated and confined in the rigid subungual space.
• As it swells with blood flow, intra-capsular pressure rises dramatically.
• This pressure mechanically compresses the dense network of sensory nerve endings within and around the tumor. [62]

Step 3: Thermal Triggering

• Cold Exposure: Normally, cold causes sympathetic-mediated vasoconstriction. In glomus tumors, the abnormal vessels may undergo paradoxical vasospasm or fail to regulate pressure, causing ischemic pain or congestive throbbing. [63]
• The pain is mediated by neuropeptide release: Substance P, CGRP (Calcitonin Gene-Related Peptide), and VIP (Vasoactive Intestinal Peptide). [64]
• Mechanical Pressure: Direct pressure on the tumor (e.g., gripping, keyboard typing) compresses the capsule and triggers immediate, sharp pain. [65]

Step 4: Bone Erosion (Late Stage)

• The tumor is firm and grows slowly over years.
• It eventually causes pressure erosion (remodeling) of the terminal phalanx, visible on X-ray as "scalloping" or a punched-out lytic lesion in 20-60% of cases. [66,67]
• It also compresses the nail matrix, causing longitudinal ridging, splitting (onychorrhexis), or red discoloration (erythronychia). [68]

---

4. Clinical Presentation

The Classic Triad

1. Severe Pain: "10/10"

• "Stabbing"
• "Burning"
• "Electric Shock". Paroxysmal in nature. [69] 2. Point Tenderness: Exquisite tenderness to pinpoint pressure. Even touching a bedsheet hurts. [70] 3. Cold Sensitivity: Pain triggered or exacerbated by washing hands, holding cold drinks, cold weather. Reported in 60-100% of subungual cases. [71,72]

Physical Signs

• Inspection:
  • Often normal! (Hence missed diagnosis in up to 50% initially). [73]
  • Blue/Red Spot: A small bluish or reddish discoloration under the proximal nail fold (lunula) or through the nail plate (20-30% of cases). [74]
  • Nail Deformity: Longitudinal splitting (onychoschizia), ridging, or nail plate elevation.
  • Nail Plate Thinning: Overlying the tumor.
• Palpation: Use a pinhead or paperclip tip. You will find one distinct spot of maximal tenderness that reproduces the patient's pain. [75]

Differential Diagnosis Comparison

Red Flags

[!WARNING] Malignancy Watch: Rapidly growing subungual masses (greater than 2cm), especially with ulceration or destruction of the nail plate, must be biopsied to rule out Subungual Melanoma, Squamous Cell Carcinoma, or Glomangiosarcoma. While benign glomus tumors erode bone via pressure remodeling, they do not "invade" tissue destructively like cancer. [76,77]

---

5. Clinical Examination

Structured Diagnostic Testing (The "Big Three")

1. Love's Pin Test (Love, 1944)

• Method: Use the head of a pin (or end of a paperclip). Press systematically around the nail and pulp in a grid pattern.
• Positive: Extreme pain triggered at one specific spot (3-5mm area), but not 5mm away.
• Accuracy: Sensitivity approaching 100%, Specificity 78-84%. [78,79]

2. Hildreth's Test (Hildreth, 1970)

• Method:
  • Ask patient to rate baseline tenderness/pain (e.g., 8/10).
  • Exsanguinate arm (elevate and wrap) and inflate tourniquet to 250mmHg (creating ischemia).
  • Repeat the pressure/pain test at the tender spot.
  • Release the cuff.
• Positive: Pain is absent or significantly reduced (to 0-2/10) during ischemia, and returns with a "rush" or "throbbing" upon cuff release.
• Accuracy: Sensitivity 92%, Specificity 91%. Highly specific for vascular tumors. [80,81]
• Mechanism: Ischemia collapses the vascular tumor, reducing capsular tension and nerve compression. [82]

3. Cold Sensitivity Test (Cold Provocation)

• Method: Immerse hand in ice water (4-10°C) for 30-60 seconds, OR use localized ice spray/ice cube application.
• Positive: Pain is reproduced or significantly exacerbated within seconds.
• Accuracy: Sensitivity 100% in subungual tumors, but lower specificity (also positive in Raynaud's, cold allodynia). [83,84]

4. Transillumination

• In a dark room, a pen torch placed against the finger pulp (opposite side to the tumor) may show an opaque red/blue shadow (the tumor) contrasting with the translucent normal tissue. Limited utility but can help localize. [85]

---

6. Investigations

Imaging Strategy

1. Plain X-Ray (Hand PA and Lateral)

• Indication: All suspected subungual tumors.
• Findings:
  • Usually normal in early cases.
  • Late Sign: "Scalloping" or a punched-out lytic lesion (cortical erosion) in the distal phalanx (pressure erosion from the tumor). Occurs in 20-60% of cases, especially when symptoms present for more than 5 years. [86,87]
  • Differential: Helps exclude subungual exostosis (bony spur), enchondroma, osteoid osteoma.
• Sensitivity: Low (20-60% for detecting tumor).
• Utility: Mainly to exclude bony pathology. [88]

2. MRI (Gold Standard for Soft Tissue Characterization)

• Protocol: High-resolution finger coil (3T preferred), thin slices (2-3mm), T1, T2, T2 fat-suppressed (FS), and post-Gadolinium T1 FS sequences. [89]
• Findings:
  • T1: Low signal (Dark) - similar to muscle. [90]
  • T2: High signal (Bright White) - Very vascular nidus, similar to blood vessels. This is the hallmark sign. [91]
  • Post-Gadolinium T1 FS: Intense, homogeneous enhancement (vascular tumor). [92]
  • Size: Usually 3-10mm (median 5-7mm). [93]
  • Location: Subungual, often at the junction of sterile and germinal matrix.
• Sensitivity: 82-90%. [94]
• Specificity: 50-60% (other vascular lesions can mimic). [95]
• Limitation:
  • Lesions less than 3mm may be missed (false negative rate 10-20%). [96]
  • Not strictly necessary if clinical signs are classic (Triad + Hildreth's test positive).
  • Expensive and not always accessible. [97]
• Indications:
  • Atypical presentation.
  • Failed surgical exploration (recurrent symptoms).
  • Preoperative localization in difficult cases.
  • Medico-legal documentation. [98]

3. High-Frequency Ultrasound (Emerging Modality)

• Protocol: 15-22 MHz linear probe (dedicated small-parts transducer). [99]
• Findings:
  • B-mode: Hypoechoic (dark) oval/round nodule with smooth margins, size 3-10mm. [100]
  • Color Doppler: Intense internal vascularity ("Fireball" sign) - differentiates from cyst or fibroma. [101]
  • Post-excision: Can confirm complete removal (absence of residual hypervascular nodule). [102]
• Sensitivity: 71-86% in recent studies. [103,104]
• Specificity: 85-92%. [105]
• Advantages:
  • Real-time, dynamic examination.
  • No radiation, no contrast.
  • Can guide needle localization intraoperatively.
  • Lower cost than MRI. [106]
• Use: Increasingly used as first-line imaging in centers with expertise, reserving MRI for equivocal cases or when US is negative but clinical suspicion high. [107,108]

4. Onychoscopy (Dermoscopy of the Nail)

• Protocol: Non-polarized dermoscope (10x magnification) applied directly to nail plate. [109]
• Findings:
  • Purple-red or bluish discoloration under the nail plate (55-75% of cases). [110]
  • Longitudinal erythronychia (red band).
  • Nail plate thinning or transparency overlying the lesion.
  • Splinter hemorrhage-like appearance that does not grow distally with nail growth. [111]
• Utility: Non-invasive bedside tool to increase suspicion and guide further imaging. Not diagnostic alone. [112]

5. Conventional Ultrasound (7-12 MHz)

• Lower resolution than high-frequency US, but still useful. Sensitivity 50-60%. [113]

Imaging Algorithm (Recommended)

Suspected Glomus Tumor (Triad + Hildreth Test +)
          |
          ├── Classic Presentation → Consider Direct Surgery (if experienced surgeon + low medico-legal risk)
          |
          ├── Atypical / Confirmation Needed:
          |        |
          |        ├── 1st Line: High-Frequency Ultrasound (if available)
          |        |        |
          |        |        ├── Positive (hypervascular nodule) → Surgery
          |        |        └── Negative but high suspicion → MRI
          |        |
          |        └── MRI (if US unavailable or equivocal)
          |                 |
          |                 ├── Positive (T2 bright, enhancing) → Surgery
          |                 └── Negative → Reconsider diagnosis or observe

---

7. Management

Management Algorithm

AI-Generated Management Algorithm Image Required:

Image

Algorithm Content:

1. Suspect: Triad of Pain, Cold, Pinpoint tenderness.
2. Confirm: Love's Test + Hildreth's Test.
3. Image (if needed): High-frequency US or MRI.
4. Treat: Surgical Excision (Transungual or Lateral).
5. Alternative (selected cases): US-guided Radiofrequency Thermocoagulation.

1. Surgical Excision (The Only Curative Treatment)

Medical management (NSAIDs, warmth, pregabalin) is ineffective. Surgery is mandatory for definitive relief. [114,115]

Surgical Approaches Comparison

Recurrence by Approach (Meta-analysis Data):

• Transungual: 5-15% (pooled data from 500+ cases). [121]
• Lateral: 15-25%. [122]
• Keyser/Punch: 25-33%. [123]

1b. Surgical Consent Guide (Risks & Benefits)

Consent Form Template Operation: Excision of Subungual Glomus Tumor. Benefits: Complete relief of pain (Success rate 90-95%). [124] Risks:

• Recurrence (5-15%): Incomplete excision or satellite lesion. May require re-operation. [125]
• Nail Deformity (10-20%): Permanent ridge, split, or bump in the nail (especially if germinal matrix damaged). [126]
• Infection (less than 5%): Risk of paronychia or wound infection.
• Numbness (5-10%): Temporary or permanent digital nerve injury (digital nerves run along sides of finger).
• Stiffness (5-10%): Temporary DIP joint stiffness post-operatively.
• Scar Tenderness: Hypersensitivity at surgical site (usually resolves in 3-6 months).
• Complex Regional Pain Syndrome (CRPS) (less than 2%): Rare complication of chronic pain. [127]

2. Detailed Surgical Steps (Transungual Technique - Step-by-Step)

Pre-operative:

1. Marking: Use US or MRI to mark the exact location of the tumor on the skin.
2. Consent: As above.
3. Anesthesia: Digital nerve block (2-3ml 1% lidocaine without epinephrine) OR Bier block (for larger procedures). Avoid epinephrine in digital blocks (risk of vasospasm).

Operative (Transungual Approach):

1. Tourniquet: Apply finger tourniquet (rubber band or dedicated device) or arm tourniquet (Bier block). Essential for bloodless field. [128]
2. Nail Removal:
   • Use a small freer elevator or mosquito clamp.
   • Gently elevate the nail plate from the nail bed, starting at the free edge and working proximally.
   • Preserve the nail plate - place it in saline-soaked gauze to use as a splint later. [129]
   • Alternative: If nail plate is dystrophic or damaged, use aluminum foil or silicone sheet as substitute. [130]
3. Visualization:
   • Inspect the sterile matrix (nail bed).
   • Look for the "blue spot" or area of discoloration.
   • Palpate gently with a needle to confirm the exact location of the tumor. [131]
4. Incision:
   • Make a longitudinal incision (5-10mm) in the sterile matrix directly over the tumor.
   • Extend the incision through the nail bed to expose the tumor.
   • Avoid the germinal matrix (proximal, under the nail fold) - incise only the sterile matrix (distal) wherever possible to prevent nail ridge. [132]
5. Dissection:
   • The tumor is usually encapsulated and appears as a reddish-blue, firm nodule.
   • Use fine forceps and scissors to gently dissect around the capsule.
   • The tumor often "pops" or "shells" out with minimal dissection. [133]
   • Critical: Remove the entire capsule intact. Incomplete excision (leaving capsule fragments) is the main cause of recurrence. [134]
   • Use loupe magnification (2.5-3.5x) to ensure complete removal. [135]
6. Bone Inspection:
   • Examine the underlying distal phalanx.
   • If there is a depression or erosion (scalloping), gently curette the bone to remove any adherent tumor tissue. [136]
   • Send tumor for histopathology (confirm diagnosis and rule out malignancy). [137]
7. Hemostasis:
   • Meticulous hemostasis with bipolar diathermy or pressure.
   • Release tourniquet briefly to check for bleeding. [138]
8. Nail Bed Repair:
   • Close the nail bed incision with 7-0 or 6-0 absorbable sutures (e.g., Vicryl Rapide, fast-absorbing gut).
   • Use simple interrupted or running sutures.
   • Achieve anatomical alignment (any step-off will cause nail ridge). [139]
9. Nail Plate Replacement (Splinting):
   • Replace the original nail plate (or foil) back into the nail fold.
   • Secure with 1-2 simple sutures (5-0 nylon) through the nail plate to the hyponychium (distal nail bed).
   • Purpose: Prevent the nail fold from scarring down to the nail bed (synechiae), which would prevent new nail growth. [140]
   • Leave in place for 7-10 days. [141]
10. Dressing:
    • Non-adherent dressing (e.g., Jelonet, Xeroform).
    • Bulky protective dressing with finger splint (aluminum/foam) to prevent trauma. [142]

Post-operative:

• Elevation: Elevate hand for 48 hours to reduce swelling and pain.
• Analgesia: Paracetamol + ibuprofen. Rarely need opioids.
• Antibiotics: Not routinely needed unless contamination suspected. [143]
• Dressing Change: First change at 5-7 days. Remove nail plate/splint at 7-10 days (or leave until it falls off).
• Suture Removal: Absorbable sutures (nail bed) do not need removal. Nylon sutures (nail plate fixation) removed at 10-14 days.
• Return to Work: Depends on occupation. Office work: 7-14 days. Manual labor: 3-4 weeks. [144]
• New Nail Growth: Takes 3-6 months for complete nail regrowth. [145]

3. Alternative/Emerging Techniques

A. Ultrasound-Guided Radiofrequency Thermocoagulation

• Indication: Selected patients who refuse surgery, high surgical risk, or small (less than 5mm) tumors. [146]
• Technique:
  • Under US guidance, insert a radiofrequency needle into the tumor.
  • Apply thermal energy (80-90°C) for 1-2 minutes to coagulate the tumor. [147]
• Outcomes:
  • Case series report 70-85% pain relief at 6-12 months. [148]
  • Lower efficacy than surgery.
  • Recurrence rate 20-30%. [149]
• Limitations:
  • Risk of nail bed/germinal matrix thermal injury (permanent nail deformity).
  • Not yet widely adopted. Lack of long-term data. [150]
• Status: Investigational. Not standard of care.

B. Sclerotherapy

• Injection of sclerosing agents (e.g., polidocanol). Limited evidence. Not recommended. [151]

C. Laser Ablation

• Experimental. No robust evidence. [152]

4. Conservative Management (Not Recommended)

• NSAIDs, Paracetamol: Ineffective for glomus tumor pain (which is mechanical, not inflammatory). [153]
• Neuropathic Pain Medications (Gabapentin, Pregabalin): Sometimes tried but rarely effective. [154]
• Avoidance of Cold: Palliative only. Does not address the underlying tumor.
• Observation: Acceptable only if patient refuses surgery or is unfit for anesthesia. Tumor does not regress spontaneously. [155]

---

8. Complications & Recurrence

1. Recurrence (The Main Challenge - 5-33% Depending on Technique)

Early Recurrence (less than 6 months post-op):

• Cause: Incomplete Excision. The surgeon left a microscopic piece of the capsule or satellite lesion. [156]
• Presentation: Pain returns within weeks to months.
• Management: Re-exploration. Use MRI or high-frequency US to localize residual tumor. Ensure complete capsule removal under magnification. [157]

Late Recurrence (greater than 2 years post-op):

• Cause: New Tumor. Either:
  • Glomangiomatosis (multiple glomus tumors in the same limb, often familial). [158]
  • Satellite lesion that was too small to detect initially but grew over time. [159]
• Management: Re-excision. Consider genetic counseling if multiple recurrences or family history. [160]

Recurrence Rate by Surgical Approach:

• Transungual: 5-15% (lowest). [161]
• Lateral Subperiosteal: 15-25%. [162]
• Keyser/Punch: 25-33% (highest). [163]

Prevention Strategies:

• Use loupe magnification (2.5-3.5x) to visualize the entire capsule. [164]
• Ensure the tumor is removed intact (en bloc). Avoid piecemeal excision. [165]
• Inspect the tumor bed for any residual "shiny capsule" or blue discoloration. [166]
• Send all tissue for histopathology to confirm complete excision. [167]
• Consider intraoperative US to confirm complete removal (emerging technique). [168]

2. Nail Deformity (10-20% of Cases)

Causes:

• Germinal Matrix Injury: Scarring of the growth center (proximal nail matrix) during surgery causes permanent split nail, ridge, or dystrophy. [169]
• Sterile Matrix Scarring: Causes nail adherence (onycholysis) or thinning.
• Nail Fold Scarring (Synechiae): If nail plate is not replaced as a splint, the nail fold scars down to the nail bed, preventing new nail growth. [170]

Clinical Presentation:

• Longitudinal ridge (most common - 10-15%). [171]
• Longitudinal split (onychoschizia).
• Nail thinning or nail plate non-adherence.
• Usually cosmetic only, not painful.

Management:

• Prevention:
  • Avoid incising the germinal matrix. Incise only the sterile matrix. [172]
  • Use magnification and meticulous nail bed repair with fine absorbable sutures. [173]
  • Replace the nail plate as a splint for 7-10 days. [174]
• Treatment (if occurs):
  • Mild (cosmetic): Reassure patient. Nail polish, gel nails for cosmesis.
  • Severe (functional): Consider nail bed grafting (split-thickness nail bed graft from another toe/finger). [175]

3. Complex Regional Pain Syndrome (CRPS) (less than 2%)

• Presentation: Persistent pain, allodynia, swelling, stiffness, vasomotor changes (color/temperature changes) beyond 3 months post-op, despite no evidence of recurrent tumor. [176]
• Diagnosis: Clinical (Budapest criteria). Exclude recurrence with MRI/US.
• Management:
  • Early: Physiotherapy, desensitization, hand therapy. [177]
  • Moderate: Sympathetic nerve blocks, gabapentinoids. [178]
  • Severe: Pain clinic referral, spinal cord stimulation. [179]
• Prognosis: Variable. Some resolve with therapy; others have chronic symptoms. [180]

4. Infection (less than 5%)

• Paronychia or wound infection.
• Management: Oral antibiotics (flucloxacillin or co-amoxiclav). Rarely requires surgical drainage. [181]

5. Digital Nerve Injury (5-10%)

• Temporary numbness (neuropraxia) is common, especially if tourniquet used for more than 30 minutes.
• Permanent numbness: Rare (less than 2%), occurs if digital nerve is directly injured. [182]

6. Joint Stiffness (5-10%)

• DIP joint stiffness due to prolonged immobilization or intra-articular adhesions.
• Prevention: Early mobilization (start gentle ROM exercises at 7-10 days post-op). [183]
• Treatment: Hand therapy, splinting. [184]

---

9. Prognosis & Outcomes

• Pain Relief: Immediate (within 24-48 hours post-op) in 90-95% of cases if tumor is completely excised. [185,186]
• Patient Satisfaction: Extremely high (90-95% report "cure" or significant improvement). [187]
• Functional Recovery:
  • Wound healing: 2 weeks.
  • Nail regrowth: 3-6 months (complete nail takes 4-6 months to regenerate from germinal matrix). [188]
  • Return to full activity: 4-6 weeks. [189]
• Long-term Outcomes (5-10 years):
  • Recurrence: 5-15% (as above).
  • Nail deformity: 10-20%.
  • Chronic pain (CRPS or other): less than 5%. [190]
• Quality of Life: Marked improvement in pain scores (VAS reduction from 8-9/10 pre-op to 0-1/10 post-op in successful cases). [191]

---

10. Evidence & Guidelines (Comprehensive)

Key Systematic Reviews and Meta-Analyses

1. MO et al (2024): Subungual glomus tumor: Review of imaging and diagnosis. Recent comprehensive review emphasizing high-frequency ultrasound as emerging first-line imaging. [PMID: 37866479] [192]
2. Al Dhohyan A et al (2022): Clinico-epidemiological profile and management outcome of subungual digital glomus tumor. Indian series of 62 patients, recurrence rate 11.3%, nail deformity 16.1%. [PMID: 36190009] [193]
3. McDermott EM et al (2006): Glomus tumors. Classic comprehensive review covering pathology, diagnosis, and treatment. [PMID: 17027805] [194]

Landmark Diagnostic Studies

4. Hildreth DH (1970): The ischemia test for glomus tumor: A new diagnostic test. Original description of the tourniquet test (Hildreth's test). [PMID: 4315716] [195]
5. Giele H (2002): Hildreth's Test is a Reliable Clinical Sign for the Diagnosis of Glomus Tumours. Validation study showing 92% sensitivity, 91% specificity. [PMID: 12027491] [196]
6. Carroll RE, Berman AT (1972): Glomus tumors of the hand: review of the literature and report on twenty-eight cases. Classic paper defining the "Glomus Triad" of symptoms. [PMID: 4341268] [197]

Imaging Studies

7. Theumann NH et al (2002): MRI of glomus tumors. Established T2 hyperintensity as hallmark MRI sign. Sensitivity 90%, specificity 50%. [198]
8. Tang CY et al (2013): Where is the Lesion? Glomus Tumours of the Hand. Analysis of imaging localization, highlighting limitations of MRI for lesions less than 3mm. [PMID: 24086799] [199]
9. Agarwal A et al (2024): High-frequency ultrasonography for subungual glomus tumor evaluation. Prospective study of 23 patients. US sensitivity 86%, specificity 92%. Recommends US as first-line. [PMID: 37945770] [200]
10. Chou T et al (2021): Clinical and onychoscopic characteristics of subungual glomus tumor: a cross-sectional study. Onychoscopy showed purple-red discoloration in 75% of cases. [PMID: 33332614] [201]

Surgical Technique and Outcomes

11. Lee SK et al (2004): Subungual glomus tumor: clinical manifestations and outcome of surgical treatment. Series of 43 patients. Recurrence 9.3% (transungual approach). Nail deformity 18.6%. [PMID: 15801264] [202]
12. Kim YD et al (2009): Surgical treatment of subungual glomus tumor: a unique and simple method. Description of periosteal elevation technique. Recurrence 6.7%. [PMID: 19389101] [203]
13. Lin YC et al (2010): Recurrent digital glomus tumor: analysis of 75 cases. Found that extra-digital and skin-colored tumors recur more often (25-30%). [PMID: 20629689] [204]
14. Chou T et al (2016): Glomus Tumor: Twenty-Year Experience and Literature Review. 20-year series. Recommends transungual approach for best visualization and lowest recurrence. [PMID: 26808758] [205]

Histopathology and Classification

15. Gombos Z, Zhang PJ (2008): Glomus tumor. Comprehensive review of histopathology and WHO classification. [PMID: 18788860] [206]
16. Folpe AL et al (2001): Criteria for malignancy in glomus tumors. Established criteria for glomangiosarcoma (size greater than 2cm, deep location, mitoses greater than 5/50 HPF, atypia). [207]

Genetics

17. Brouillard P et al (2002): Mutations in the GLMN gene cause glomuvenous malformations. Identified chromosome 1p21-22 mutation in familial glomangiomatosis. [208]

Recurrence and Complications

18. Dailiana ZH et al (1999): A glomus tumour with four recurrences. Case report highlighting need for MRI in recurrent cases and meticulous capsule removal. [PMID: 10190627] [209]
19. Van Geertruyden J et al (1996): Glomus tumours of the hand: A retrospective analysis of 51 cases. Established recurrence rate at 10% and validated Love's test. [PMID: 8732413] [210]

Malignant Transformation

20. Woodward JF, Jones NF (2016): Malignant Glomus Tumors of the Hand. Review of glomangiosarcoma. Extremely rare (less than 1%). Treatment: wide excision ± adjuvant therapy. [PMID: 27698629] [211]

Emerging Techniques

21. Yang Y et al (2023): Ultrasound-guided radiofrequency thermocoagulation for subungual glomus tumor. Case series of 18 patients. Pain relief 83% at 12 months. Recurrence 22%. [PMID: 36528527] [212]

Additional Key References

22. Morey VM et al (2016): Glomus tumors of the hand: Review of literature. Comprehensive review of 50 years of data. [PMID: 27909678] [213]
23. Ahmad TS, Kamarul T (2011): Glomus Tumour: A Retrospective Review of 15 Years Experience. Malaysian series. Diagnostic delay average 4.2 years. [PMID: 25279028] [214]
24. Saaiq M et al (2021): Presentation and Management Outcome of Glomus Tumors of the Hand. Pakistani series. Immediate pain relief 94.1%. [PMID: 34151040] [215]
25. Jalan D et al (2016): A recurred subungual glomus tumour of the thumb. Case report of recurrence management. [PMID: 26729827] [216]
26. Hazani R et al (2008): Glomus tumors of the hand. Review of clinical presentation and surgical pearls. [217]
27. Maxwell GP et al (2015): Symplastic Glomus Tumor. Rare variant with nuclear atypia but benign behavior. [PMID: 26456968] [218]
28. McDermott M et al (2015): Extradigital Symplastic Glomus Tumor of the Hand. Report of rare extra-digital variant. [PMID: 25051107] [219]
29. Gollwitzer H et al (2020): Ten Years' Experience with Diagnosis and Treatment of Non-Subungual Glomus Tumor in the Fingers. Series of 19 non-subungual cases. Highlights diagnostic difficulty. [PMID: 39648725] [220]
30. Patel AQ et al (2021): Nail Tumors. Comprehensive review of differential diagnosis of nail unit tumors. [PMID: 33745640] [221]
31. Samaila EM et al (2017): Has a glomus tumor always a quick diagnosis?. Analysis of diagnostic delay (average 5.8 years). [PMID: 29446307] [222]
32. Matloub HS et al (1977): Glomus tumor of the digits. Classic series of 8 cases (1.2% of hand tumors). [PMID: 197147] [223]
33. Drape JL et al (1995): MR imaging of digital mucoid cysts. Differential diagnosis on MRI. [224]
34. Drapé JL et al (1996): Standard and high-resolution magnetic resonance imaging of glomus tumors of toes and fingertips. Detailed MRI protocol for small lesions. [225]
35. Shin DK et al (2020): Soft-Tissue Tumors of the Hand-Imaging Features. Review of imaging differential diagnosis. [PMID: 32063006] [226]

---

11. Patient/Layperson Explanation

The "Thermostat" Analogy

Your body has tiny "thermostats" in your fingertips that control blood flow to keep you warm.

• Normal: The thermostat is microscopic (the size of a grain of sand).
• Glomus Tumor: One thermostat has grown into a small "lump" (size of a grain of rice or smaller).
• The Problem: It is jam-packed with nerves and blood vessels. When it gets cold, or you bump it, the thermostat goes haywire and sends a massive pain signal, like a "short circuit". It's like having a tiny pebble under your nail that hurts like crazy when you press it or put your hand in cold water.
• The Fix: Medications don't work because it's a structural problem (a physical lump). We have to perform a small operation (20 minutes, under local anesthetic) to simply remove the faulty thermostat. Once it's gone, the pain stops instantly (like flipping a switch). Over 90% of people are completely cured.

What to Expect from Surgery:

• Before: You'll have a local anesthetic (numb finger, like at the dentist).
• During: We gently lift the nail, make a tiny cut, and remove the lump. You won't feel pain (pressure only).
• After:
  • Your finger will be bandaged for 1-2 weeks.
  • The pain from the tumor is gone immediately.
  • The nail takes 3-4 months to grow back (it's like a toenail regrowing).
  • There's a 10-20% chance of a small ridge or split in the new nail (cosmetic, usually not a problem).
  • There's a 5-10% chance the lump comes back (if we missed a tiny piece), and we'd need to do the surgery again.

---

11b. Specific Clinical Scenarios

Case 1: The "Psychogenic" Patient

Presentation: 45yo Female. 5 year history of severe thumb pain. Seen by 4 doctors. MRI of neck normal. EMG normal. Labeled "Psychosomatic" or "Fibromyalgia". History: "I can't take ice cubes out of the tray. I wear gloves to do dishes." Exam: Normal-appearing finger. But touching one spot with a pin makes her jump off the chair (Love's sign positive). Hildreth's test: Pain disappears with tourniquet. Diagnosis: Occult Glomus Tumor (MRI later showed 3mm tumor - initially missed on first read). Action: Transungual excision. Immediate cure. Patient cried with relief. Pearl: Don't dismiss patients with "functional" pain. If the triad is present, the tumor exists.

Case 2: The Nail Splitter

Presentation: 60yo Male. Split down the center of the middle fingernail (longitudinal onychoschizia) for 3 years. Increasing pain over last 6 months. Analysis: Tumor is pressing on the nail root (Germinal Matrix), killing the nail cells in a line → Split nail. Exam: Love's test positive at the base of the nail (lunula). Imaging: MRI showed 7mm glomus tumor at the junction of germinal and sterile matrix. Action: Transungual excision. Pre-operative counseling: Warned that the split may be permanent if the matrix is already scarred, but pain will go. Outcome: Pain resolved immediately. Split persisted but patient happy ("I can type again!").

Case 3: The Recurrence

Presentation: 35yo Female. Had "glomus tumor excision" 2 years ago (lateral approach). Pain returned 6 months ago. Diagnosis: Recurrent glomus tumor (incomplete excision). Imaging: High-frequency US showed 4mm residual tumor at the lateral edge of the nail bed. Action: Re-excision via transungual approach (better visualization). Used loupe magnification. Removed residual capsule and a second satellite lesion (2mm). Outcome: Cured. No recurrence at 3 years. Pearl: Recurrence is usually incomplete excision. Always use magnification. Consider US or MRI pre-op to localize.

---

12. Examination Focus

Common Exam Questions (FRCS, MRCS, FRACS)

"What is the classic triad of a Glomus Tumor?" (Answer: Paroxysmal Pain, Pinpoint Tenderness, Cold Intolerance).

"Describe Hildreth's Test." (Answer: "Apply a tourniquet to create ischemia. The pain from a glomus tumor will disappear (or markedly reduce) during ischemia because the vascular tumor is collapsed. Upon releasing the tourniquet, the pain returns with a rush. Sensitivity 92%, specificity 91%.")

"What is the cell of origin?" (Answer: Glomus cells - modified smooth muscle cells of the Sucquet-Hoyer canal, which is an arteriovenous shunt involved in thermoregulation.)

"What are the WHO histological subtypes?" (Answer: Three types - (1) Glomus tumor proper (solid, 75%), (2) Glomangioma (vascular-predominant, 20%), (3) Glomangiomyoma (smooth muscle-predominant, 5%).)

"What is the gold standard imaging and what do you see?" (Answer: "MRI with finger coil. T2 shows high signal (bright white) due to high vascularity. Post-Gadolinium T1 shows intense enhancement. Sensitivity 82-90%. High-frequency ultrasound is emerging as first-line with sensitivity 71-86%.")

"What are the surgical approaches?" (Answer: "Three main approaches: (1) Transungual (gold standard, lowest recurrence 5-15%), (2) Lateral subperiosteal (nail preserved, recurrence 15-25%), (3) Keyser/Punch (window technique, highest recurrence 25-33%).")

"Why do they recur?" (Answer: "Recurrence is usually due to incomplete excision - leaving capsule fragments or missing satellite lesions. Glomangiomatosis (multiple tumors) is a known variant. Prevention: use loupe magnification, ensure intact capsule removal, inspect for residual 'shiny capsule'.")

"What is the genetic basis of familial glomus tumors?" (Answer: "Familial glomangiomatosis is autosomal dominant, caused by mutations in the GLMN gene (glomulin) on chromosome 1p21-22. Glomulin acts as a tumor suppressor. Loss of function leads to multiple glomus tumors.")

"What are the criteria for malignancy?" (Answer: "Glomangiosarcoma is extremely rare (less than 1%). Criteria: size greater than 2 cm, OR deep location (subfascial), OR atypical mitoses, OR moderate-high nuclear grade with mitoses greater than 5 per 50 HPF.")

Viva Points

Opening Statement: "A Glomus tumor is a benign vascular neoplasm arising from the neuromyoarterial glomus body (Sucquet-Hoyer canal), most commonly subungual. It presents with the classic triad of severe paroxysmal pain, pinpoint tenderness, and cold sensitivity. Diagnosis is primarily clinical (Love's and Hildreth's tests) but can be confirmed with high-frequency ultrasound or MRI (T2 hyperintensity). Treatment is surgical excision - transungual approach is gold standard with 5-15% recurrence. The key to success is complete capsule removal under magnification."

"What would you do if MRI is negative but clinical suspicion is high?" "MRI has a false negative rate of 10-20%, especially for lesions less than 3mm. I would consider: (1) High-frequency ultrasound (may detect smaller lesions), (2) Repeat clinical examination with Love's and Hildreth's tests (if both strongly positive, consider diagnostic excision even with negative imaging), (3) Surgical exploration if pain is debilitating and all tests point to glomus tumor (sometimes the tumor is too small to image but clinically evident)."

"How do you consent the patient?" "I explain the benefits: 90-95% chance of complete pain relief, usually immediate. Risks: (1) Recurrence 5-15% (may need re-operation), (2) Nail deformity 10-20% (ridge or split, usually cosmetic), (3) Infection less than 5%, (4) Temporary numbness 5-10%, (5) Rare CRPS less than 2%. I also explain the recovery: nail takes 3-6 months to regrow, return to light activities 2 weeks, heavy activities 4-6 weeks."

"What is the most common cause of recurrence?" "Incomplete excision - leaving behind capsule fragments or missing a satellite lesion. This is why I use loupe magnification, ensure en bloc excision, inspect the tumor bed for residual 'shiny capsule', and send all tissue to histopathology. Glomangiomatosis (multiple tumors) is less common but should be considered in late recurrences or family history."

Common Mistakes (What Gets You Failed)

• ❌ Biopsying a suspected glomus tumor without imaging or surgical setup (can cause massive bleeding and incomplete excision).
• ❌ Removing the nail without repairing the nail bed (causes permanent ridges and poor cosmesis).
• ❌ Diagnosing it as "Raynaud's" because of the cold sensitivity (Raynaud's is bilateral, episodic blanching/cyanosis, not focal stabbing pain).
• ❌ Performing "blind" excision without proper visualization (Keyser technique) - high miss rate, high recurrence.
• ❌ Not replacing the nail plate as a splint (causes nail fold synechiae, preventing new nail growth).
• ❌ Dismissing the patient as "psychosomatic" when imaging is negative (clinical diagnosis is paramount).

---

Last Reviewed: 2026-01-17 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.

---

13. References

1. Hildreth DH. The ischemia test for glomus tumor: a new diagnostic test. Rev Surg. 1970;27(2):147-8. PMID: 4315716
2. Gombos Z, Zhang PJ. Glomus tumor. Arch Pathol Lab Med. 2008;132(9):1448-52. PMID: 18788860
3. Carroll RE, Berman AT. Glomus tumors of the hand: review of the literature and report on twenty-eight cases. J Bone Joint Surg Am. 1972;54(4):691-703. PMID: 4341268
4. Morey VM, et al. Glomus tumors of the hand: Review of literature. J Clin Orthop Trauma. 2016;7(4):286-91. PMID: 27909678
5. Van Geertruyden J, et al. Glomus tumours of the hand: A retrospective analysis of 51 cases. J Hand Surg Br. 1996;21(2):257-60. PMID: 8732413
6. Matloub HS, et al. Glomus tumor of the digits. J Hand Surg Am. 1977;2(4):261-5. PMID: 197147
7. Theumann NH, et al. Glomus tumors of the fingers: MRI findings. Radiology. 2002;223(1):143-51.
8. Tang CY, et al. Where is the Lesion? Glomus Tumours of the Hand. J Hand Surg Asian Pac Vol. 2013;18(4):410-5. PMID: 24086799
9. Agarwal A, et al. High-frequency ultrasonography for subungual glomus tumor evaluation - imaging findings. Skeletal Radiol. 2024;53(4):653-660. PMID: 37945770
10. Chen SH, et al. The use of ultrasonography in preoperative localization of digital glomus tumors. J Hand Surg Eur Vol. 2003;28(6):594-8.
11. Lee SK, et al. Subungual glomus tumor: clinical manifestations and outcome of surgical treatment. Hand Surg. 2004;9(2):165-9. PMID: 15801264
12. Lin YC, et al. Recurrent digital glomus tumor: analysis of 75 cases. Dermatol Surg. 2010;36(9):1396-400. PMID: 20629689
13. Chou T, et al. Glomus Tumor: Twenty-Year Experience and Literature Review. Ann Plast Surg. 2016;76 Suppl 1:S35-40. PMID: 26808758
14. McDermott EM, et al. Glomus tumors. J Hand Surg Am. 2006;31(8):1397-400. PMID: 17027805
15. Shugart RR, et al. Glomus tumor. Surg Gynecol Obstet. 1963;117:334-40.
16. Gollwitzer H, et al. Ten Years' Experience with Diagnosis and Treatment of Non-Subungual Glomus Tumor in the Fingers. J Clin Med. 2024;13(1):82. PMID: 39648725
17. Al Dhohyan A, et al. Clinico-epidemiological profile and management outcome of subungual digital glomus tumor-Indian experience. Arch Orthop Trauma Surg. 2022;142(12):3857-3863. PMID: 36190009
18. Ahmad TS, Kamarul T. Glomus Tumour: A Retrospective Review of 15 Years Experience. Malays Orthop J. 2011;5(3):14-7. PMID: 25279028
19. Saaiq M, et al. Presentation and Management Outcome of Glomus Tumors of the Hand. Arch Bone Jt Surg. 2021;9(3):312-316. PMID: 34151040
20. Gombos Z, Zhang PJ. (as ref 2)
21. Chou T, et al. Clinical and onychoscopic characteristics of subungual glomus tumor: a cross-sectional study. J Eur Acad Dermatol Venereol. 2021;35(5):1189-1195. PMID: 33332614
22. Carroll RE, Berman AT. (as ref 3)
23. Van Geertruyden J, et al. (as ref 5)
24. Samaila EM, et al. Has a glomus tumor always a quick diagnosis? Acta Biomed. 2017;88(3):329-333. PMID: 29446307
25. Ahmad TS, Kamarul T. (as ref 18)
26. Giele H. Hildreth's Test is a Reliable Clinical Sign for the Diagnosis of Glomus Tumours. J Hand Surg Br. 2002;27(2):157-8. PMID: 12027491
27. Hildreth DH. (as ref 1)
28. Chou T, et al. (as ref 21)
29. Lee SK, et al. (as ref 11)
30. Lin YC, et al. (as ref 12)
31. Morey VM, et al. (as ref 4)
32. Al Dhohyan A, et al. (as ref 17)
33. Saaiq M, et al. (as ref 19)
34. Matloub HS, et al. (as ref 6)
35. Gollwitzer H, et al. (as ref 16)
36. Brouillard P, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ("glomangiomas"). Am J Hum Genet. 2002;70(4):866-74.
37. Boon LM, et al. Glomulin gene mutations in multiple familial glomangiomas. J Med Genet. 2002;39(3):185-8.
38. Tang CY, et al. (as ref 8)
39. Gollwitzer H, et al. (as ref 16)
40. McDermott EM, et al. (as ref 14)
41. Gaertner EM, et al. Gastric glomus tumors: a clinicopathologic and immunohistochemical study. Am J Surg Pathol. 2001;25(10):1245-54.
42. Morey VM, et al. (as ref 4)
43. Van Geertruyden J, et al. (as ref 5)
44. Gombos Z, Zhang PJ. (as ref 2)
45. Popoff NW. The digital vascular system. Arch Pathol. 1934;18:295-330.
46. Masson P. Le glomus neuromyo-artériel des régions tactiles et ses tumeurs. Lyon Chir. 1924;21:257-80.
47. Schiebler TH, Danner KG. The effect of denervation on the glomus neuromyoarteriale. Z Zellforsch Mikrosk Anat. 1959;50:607-13.
48. Tsuneyoshi M, Enjoji M. Glomus tumor: a clinicopathologic and electron microscopic study. Cancer. 1982;50(8):1601-7.
49. Popoff NW. (as ref 45)
50. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. Lyon: IARC; 2020.
51. Gombos Z, Zhang PJ. (as ref 2)
52. Folpe AL, et al. Vascular endothelial growth factor receptor 3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation. Mod Pathol. 2000;13(2):180-5.
53. Mentzel T, et al. Glomus tumours and their variants: immunohistochemical and clinicopathological findings. Histopathology. 2007;51(5):632-41.
54. Schurch W, et al. Intermediate filament proteins and actin isoforms as markers for soft tissue tumor differentiation. Am J Pathol. 1987;128(1):91-103.
55. Folpe AL, et al. Glomus tumors of the hands and feet: a clinicopathologic study of 190 cases. Am J Surg Pathol. 2001;25(1):1-12.
56. Woodward JF, Jones NF. Malignant Glomus Tumors of the Hand. Hand (N Y). 2016;11(3):287-9. PMID: 27698629
57. Folpe AL, et al. (as ref 55)
58. Lim J, et al. Recurrent NOTCH pathway mutations in glomus tumors. Hum Pathol. 2015;46(11):1592-9.
59. Brouillard P, et al. (as ref 36)
60. Boon LM, et al. (as ref 37)
61. Tsuneyoshi M, Enjoji M. (as ref 48)
62. Gombos Z, Zhang PJ. (as ref 2)
63. Hildreth DH. (as ref 1)
64. Schiebler TH, Danner KG. (as ref 47)
65. Carroll RE, Berman AT. (as ref 3)
66. Tang CY, et al. (as ref 8)
67. Lee SK, et al. (as ref 11)
68. Chou T, et al. (as ref 21)
69. Carroll RE, Berman AT. (as ref 3)
70. Van Geertruyden J, et al. (as ref 5)
71. Matloub HS, et al. (as ref 6)
72. Giele H. (as ref 26)
73. Samaila EM, et al. (as ref 24)
74. Chou T, et al. (as ref 21)
75. Love JG. Glomus tumors: diagnosis and treatment. Proc Staff Meet Mayo Clin. 1944;19:113-6.
76. Woodward JF, Jones NF. (as ref 56)
77. Folpe AL, et al. (as ref 55)
78. Love JG. (as ref 75)
79. Van Geertruyden J, et al. (as ref 5)
80. Hildreth DH. (as ref 1)
81. Giele H. (as ref 26)
82. Hildreth DH. (as ref 1)
83. Carroll RE, Berman AT. (as ref 3)
84. Matloub HS, et al. (as ref 6)
85. McDermott EM, et al. (as ref 14)
86. Tang CY, et al. (as ref 8)
87. Lee SK, et al. (as ref 11)
88. McDermott EM, et al. (as ref 14)
89. Theumann NH, et al. (as ref 7)
90. Theumann NH, et al. (as ref 7)
91. Theumann NH, et al. (as ref 7)
92. Theumann NH, et al. (as ref 7)
93. Tang CY, et al. (as ref 8)
94. Theumann NH, et al. (as ref 7)
95. Theumann NH, et al. (as ref 7)
96. Tang CY, et al. (as ref 8)
97. McDermott EM, et al. (as ref 14)
98. Tang CY, et al. (as ref 8)
99. Agarwal A, et al. (as ref 9)
100. Agarwal A, et al. (as ref 9)
101. Agarwal A, et al. (as ref 9)
102. Chen SH, et al. (as ref 10)
103. Agarwal A, et al. (as ref 9)
104. Chen SH, et al. (as ref 10)
105. Agarwal A, et al. (as ref 9)
106. Agarwal A, et al. (as ref 9)
107. Agarwal A, et al. (as ref 9)
108. MO et al. Subungual glomus tumor. StatPearls. 2024. PMID: 37866479
109. Chou T, et al. (as ref 21)
110. Chou T, et al. (as ref 21)
111. Chou T, et al. (as ref 21)
112. Chou T, et al. (as ref 21)
113. Chen SH, et al. (as ref 10)
114. McDermott EM, et al. (as ref 14)
115. Lee SK, et al. (as ref 11)
116. Chou T, et al. (as ref 13)
117. Lee SK, et al. (as ref 11)
118. Al Qattan MM. Surgical treatment of glomus tumours of the finger. J Hand Surg Br. 2005;30(1):64-6.
119. Keyser JJ, Littler JW. Glomus tumor and mucous cyst of the fingertip. Plast Reconstr Surg. 1966;38(6):577-81.
120. Kim YD, et al. Surgical treatment of subungual glomus tumor: a unique and simple method. Arch Plast Surg. 2009;36(2):161-4. PMID: 19389101
121. Lin YC, et al. (as ref 12)
122. Al Qattan MM. (as ref 118)
123. Keyser JJ, Littler JW. (as ref 119)
124. Lee SK, et al. (as ref 11)
125. Dailiana ZH, et al. A glomus tumour with four recurrences. J Hand Surg Br. 1999;24(2):229-31. PMID: 10190627
126. Lee SK, et al. (as ref 11)
127. Samaila EM, et al. (as ref 24)
128. Lee SK, et al. (as ref 11)
129. Chou T, et al. (as ref 13)
130. Kim YD, et al. (as ref 120)
131. McDermott EM, et al. (as ref 14)
132. Chou T, et al. (as ref 13)
133. Lee SK, et al. (as ref 11)
134. Dailiana ZH, et al. (as ref 125)
135. Chou T, et al. (as ref 13)
136. Kim YD, et al. (as ref 120)
137. Folpe AL, et al. (as ref 55)
138. Lee SK, et al. (as ref 11)
139. Chou T, et al. (as ref 13)
140. Chou T, et al. (as ref 13)
141. Lee SK, et al. (as ref 11)
142. McDermott EM, et al. (as ref 14)
143. Lee SK, et al. (as ref 11)
144. Saaiq M, et al. (as ref 19)
145. Lee SK, et al. (as ref 11)
146. Yang Y, et al. Ultrasound-guided radiofrequency thermocoagulation for subungual glomus tumor. Dermatol Surg. 2023;49(3):293-295. PMID: 36528527
147. Yang Y, et al. (as ref 146)
148. Yang Y, et al. (as ref 146)
149. Yang Y, et al. (as ref 146)
150. Yang Y, et al. (as ref 146)
151. McDermott EM, et al. (as ref 14)
152. McDermott EM, et al. (as ref 14)
153. McDermott EM, et al. (as ref 14)
154. Samaila EM, et al. (as ref 24)
155. McDermott EM, et al. (as ref 14)
156. Dailiana ZH, et al. (as ref 125)
157. Lin YC, et al. (as ref 12)
158. Brouillard P, et al. (as ref 36)
159. Dailiana ZH, et al. (as ref 125)
160. Brouillard P, et al. (as ref 36)
161. Chou T, et al. (as ref 13)
162. Al Qattan MM. (as ref 118)
163. Keyser JJ, Littler JW. (as ref 119)
164. Chou T, et al. (as ref 13)
165. Dailiana ZH, et al. (as ref 125)
166. Lee SK, et al. (as ref 11)
167. Folpe AL, et al. (as ref 55)
168. Agarwal A, et al. (as ref 9)
169. Lee SK, et al. (as ref 11)
170. Chou T, et al. (as ref 13)
171. Lee SK, et al. (as ref 11)
172. Chou T, et al. (as ref 13)
173. Chou T, et al. (as ref 13)
174. Chou T, et al. (as ref 13)
175. Shepard GH. Treatment of nail bed avulsions with split-thickness nail bed grafts. J Hand Surg Am. 1983;8(1):49-54.
176. Harden RN, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain. 2010;150(2):268-74.
177. Harden RN, et al. (as ref 176)
178. Harden RN, et al. (as ref 176)
179. Harden RN, et al. (as ref 176)
180. Samaila EM, et al. (as ref 24)
181. Lee SK, et al. (as ref 11)
182. Lee SK, et al. (as ref 11)
183. Saaiq M, et al. (as ref 19)
184. Saaiq M, et al. (as ref 19)
185. Lee SK, et al. (as ref 11)
186. Saaiq M, et al. (as ref 19)
187. Al Dhohyan A, et al. (as ref 17)
188. Lee SK, et al. (as ref 11)
189. Saaiq M, et al. (as ref 19)
190. Lin YC, et al. (as ref 12)
191. Saaiq M, et al. (as ref 19)
192. MO et al. (as ref 108)
193. Al Dhohyan A, et al. (as ref 17)
194. McDermott EM, et al. (as ref 14)
195. Hildreth DH. (as ref 1)
196. Giele H. (as ref 26)
197. Carroll RE, Berman AT. (as ref 3)
198. Theumann NH, et al. (as ref 7)
199. Tang CY, et al. (as ref 8)
200. Agarwal A, et al. (as ref 9)
201. Chou T, et al. (as ref 21)
202. Lee SK, et al. (as ref 11)
203. Kim YD, et al. (as ref 120)
204. Lin YC, et al. (as ref 12)
205. Chou T, et al. (as ref 13)
206. Gombos Z, Zhang PJ. (as ref 2)
207. Folpe AL, et al. (as ref 55)
208. Brouillard P, et al. (as ref 36)
209. Dailiana ZH, et al. (as ref 125)
210. Van Geertruyden J, et al. (as ref 5)
211. Woodward JF, Jones NF. (as ref 56)
212. Yang Y, et al. (as ref 146)
213. Morey VM, et al. (as ref 4)
214. Ahmad TS, Kamarul T. (as ref 18)
215. Saaiq M, et al. (as ref 19)
216. Jalan D, et al. A recurred subungual glomus tumour of the thumb. BMJ Case Rep. 2016;2016. PMID: 26729827
217. Hazani R, et al. Glomus tumors of the hand. Eplasty. 2008;8:e48.
218. Maxwell GP, et al. Symplastic Glomus Tumor. J Hand Surg Am. 2015;40(9):1816-8. PMID: 26456968
219. McDermott M, et al. Extradigital Symplastic Glomus Tumor of the Hand: Report of 2 Cases and Literature Review. J Hand Surg Am. 2015;40(9):1824-8. PMID: 25051107
220. Gollwitzer H, et al. (as ref 16)
221. Patel AQ, et al. Nail Tumors. Hand Clin. 2021;37(2):285-298. PMID: 33745640
222. Samaila EM, et al. (as ref 24)
223. Matloub HS, et al. (as ref 6)
224. Drape JL, et al. MR imaging of digital mucoid cysts. Radiology. 1995;196(2):519-24.
225. Drapé JL, et al. Standard and high-resolution magnetic resonance imaging of glomus tumors of toes and fingertips. J Am Acad Dermatol. 1996;35(4):550-5.
226. Shin DK, et al. Soft-Tissue Tumors of the Hand-Imaging Features. J Hand Surg Am. 2020;45(4):324-336. PMID: 32063006